Currently, the major approved CAR-T cell therapy targets are B cell maturation antigen (BCMA) for multiple myeloma (MM) (5) and CD19 for various lymphoid malignancies including B-ALL and diffuse large B-cell lymphoma (DLBCL) (6–9). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.